Home / Health / New Nanoinjection Fights Breast Cancer Smarter
New Nanoinjection Fights Breast Cancer Smarter
23 Dec
Summary
- A nanoinjection platform precisely targets breast cancer cells.
- It uses 23 times less drug than traditional methods.
- The technology is biocompatible and non-toxic silicon nanotubes.
Scientists have developed a groundbreaking nanoinjection drug delivery platform aimed at revolutionizing breast cancer treatment. This innovative system, created by researchers from IIT Madras, Monash University, and Deakin University, precisely targets cancerous cells, thereby minimizing harm to healthy tissues. The platform encapsulates anti-cancer drugs within nanoarchaeosomes and delivers them via silicon nanotubes.
Experimental results have shown remarkable efficacy, with the nanoinjection platform exhibiting 23 times lower inhibitory concentration compared to free doxorubicin. This suggests a potential for significantly higher potency at much lower doses, which could lead to reduced treatment costs and fewer adverse side effects for patients. The use of silicon nanotubes ensures the platform is inherently biocompatible and non-toxic.
This advancement holds particular promise for low- and middle-income countries where access to advanced cancer therapies is often limited by cost. Researchers anticipate the patented technology could see translation within the next five years, with ongoing work focused on in vivo validation and its effectiveness against different cancer types.
